Search hospitals > Texas > Houston
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Claim this profileHouston, Texas 77030
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Leukemia
Conducts research for Lymphoma
295 reported clinical trials
47 medical researchers
Summary
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 496 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Jennifer Foster, MDBaylor College of Medicine/Dan L Duncan Comprehensive Cancer Center1 year of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
33 reported clinical trials
49 drugs studied
Patricia Baxter, MDTexas Children's Hospital2 years of reported clinical research
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
31 reported clinical trials
39 drugs studied
Mothaffar Rimawi, MDBaylor College of Medicine5 years of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
22 drugs studied
Ahmed ElkhananyUniversity of Alabama at Birmingham Cancer Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Breast Cancer
Cancer
Osteosarcoma
Non-Small Cell Lung Cancer
Brain Tumor
Rhabdomyosarcoma
Lung Cancer
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Lymphoma
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center?
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Tumors, Recurrence, Leukemia, Lymphoma and other specialties. Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center is involved with conducting 295 clinical trials across 496 conditions. There are 47 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Mothaffar Rimawi, MD, and Ahmed Elkhanany.